Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of ivonescimab (AK112), a first-in-class bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), administered alongside the CapeOX chemotherapy regimen (capecitabine and oxaliplatin) and radiotherapy. It is currently being evaluated in a Phase II clinical trial (NCT05795387) sponsored by Fudan University for the treatment of patients with unresectable metastatic microsatellite stable (MSS) colorectal cancer. The regimen aims to leverage the synergistic effects of dual checkpoint and angiogenesis inhibition with cytotoxic chemotherapy, potentially enhanced by the abscopal effects of radiotherapy, to overcome the typically immunosuppressive microenvironment of MSS colorectal tumors.
- Other names
- AK112 + CapeOXivonescimab + CapeOXAK112 with CapeOX and RadiotherapyAK-112 with CapeOX and RadiotherapyAK 112 with CapeOX and Radiotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on ivonescimab + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + capecitabine + oxaliplatin.